Greenwich LifeSciences ( (GLSI) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Greenwich LifeSciences, Inc. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The company is seeking a brief extension for this annual filing and confirms that all other required reports over the past year have been submitted on time.
The company explains that it cannot file the Form 10-K (Yearly Report) within the original deadline without unreasonable effort or expense. While no detailed internal or external issues are cited, the delay appears procedural rather than the result of a reported control failure, auditor change, or governance dispute.
Greenwich LifeSciences states it expects to file the delayed Form 10-K (Yearly Report) by April 15, 2025, which falls within the 15-calendar-day grace period allowed under SEC Rule 12b-25. Investors should view this as a short-term timing issue rather than an open-ended delay, assuming the company meets this revised target.
The company flags that it anticipates a significant change in results of operations compared to the prior year. Research and development expenses are expected to rise by about $4.6 million, or roughly 35%, to approximately $17.5 million for 2025, mainly driven by higher clinical spending on its Phase III trial.
Management notes that these figures are still under review and could change in the final Form 10-K (Yearly Report), underscoring their preliminary and forward-looking nature. Shareholders should be aware that the ultimate reported numbers may differ once all audit and review procedures are completed.
Greenwich LifeSciences emphasizes that it is proceeding under the formal SEC extension framework to remain in compliance while it completes the annual report. The notification is signed by Chief Executive Officer Snehal Patel on March 31, 2026, affirming executive-level oversight of the delayed filing and the company’s intention to complete the process promptly.
The most recent analyst rating on (GLSI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Greenwich LifeSciences stock, see the GLSI Stock Forecast page.
More about Greenwich LifeSciences
Average Trading Volume: 373,412
Technical Sentiment Signal: Buy
Current Market Cap: $297.7M
See more insights into GLSI stock on TipRanks’ Stock Analysis page.